Longitudinal surveillance and combination antimicrobial susceptibility testing of multidrug-resistant achromobacter spp. from cystic fibrosis patients.

Conclusions: This study enriches the understanding of MDR Achromobacter spp. epidemiology, confirms prevalence and chronic colonization of A. xylosoxidans in CF lungs. It presents in vitro data to support the efficacy of new combinations for use in the treatment of chronic Achromobacter infections. PMID: 32816722 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32816722?dopt=Abstract

Source: Antimicrobial Agents and Chemotherapy - August 16, 2020 Category: Microbiology Authors: Okoliegbe IN, Hijazi K, Cooper K, Ironside C, Gould IM Tags: Antimicrob Agents Chemother Source Type: research